ENDOMETRIAL CANCER COMMITTEE
AGENDA
Gynecologic Cancer Intergroup (GCIG)
GCIG Autumn 2010
3:30 p.m. – 4:30 p.m., October 21, 2010
Corinthia Hotel, Prague
Tiber-Seine-Rhine Room
Chairs: David Miller & Ketta Lorusso
PROPOSED GCIG STUDIES FOR REVIEW:
Staging
LYTEC/NESTEC: LYmphadenectomy Trial in Endometrial Cancer
Advanced/recurrent:
GOG:
GOG-0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent
Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the
Uterine Corpus – RTOG participating. NCRI & SWOG interested.
NCIC CTG EN 8: Randomized Phase III Study of progestational hormone
therapy versus deforolimus in women with recurrent or metastatic endometrial
cancer – Interested groups: ACRIN, AGO-AUST, AGO-OVAR, ANZOG,
EORTC, GEICO, GINECO, JGOG, MANGO, MITO, NCRI, NSGO, SWOG
Trophoblastic neoplasia:
ANZGOG:
1.CHM with neg HCG 8 weeks post evacuation
2.PHM reaching neg HCG
1
The diagnosis of molar pregnancy has a major impact on women’s lives. Not only is
pregnancy loss a major issue but the need for often prolonged follow up and resultant
delay in fertility compounds the situation.
An analysis of the Hydatidiform Mole Registry 1,2 results in Melbourne, Australia has
revealed no case of persistent trophoblast disease if the HCG is normalised by 8 weeks
in Complete Moles and once it is normal in Partial Moles.
Validation of the safety of these observations could be.undertaken by cross registry
analysis or alternatively by a randomised trial in which patients are randomised to
current local policy or to discontinuation of follow up according to the above findings.
The end points would be a comparison of the incidence of persistent GTN in either arm.
1. Kerkmeiier L, Wiesma S, Bekkers R, Pyman J, Tan J, Quinn M (2006) Guidelines
following hydatidiform mole: a reappraisal. Aust NZ J Obstet Gynaecol 46(2):112-118.
2. Wiesma S, Kerkmeiier, Bekkers R, Tan J, Pyman J and Quinn M (2006) Persistent
Trophoblast Disease following Partial Molar Pregnancy Aust NZ J Obstet Gynaecol 46
119-123
GOG:
UC1005: A sequential phase II/III randomized trial comparing three widely used
regimens for the management of low risk gestational trophoblastic neoplasia
UPDATE ON ACTIVE STUDIES:
AGO:
AGO-GYN 5: Antitumoral Activity and Safety of AEZS-108 in Women with LHRH
Receptor Positive Gynecological Tumors
DGOG:
PORTEC-3: Randomized Phase III Trial Comparing Concurrent Chemoradiation and
Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage
Endometrial Carcinoma – Participating groups: MaNGO, ANZGOG, NCRI, and NCICCTG. NSGO interested.
GOG:
2
GOG-0242: A Phase II Study to Determine the Response to Second Curettage
as Initial Management for Persistent Low Risk, Non-Metastatic Gestational
Trophoblastic Neoplasia
GOG-0248: A Randomized Phase II Trial of Temsirolimus or the Combination of
Hormonal Therapy Plus Temsirolimus in Women with Advanced or Recurrent
Endometrial Carcinoma
GOG-0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff
Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High
Risk, Early Stage Endometrial Cancer – RTOG would like to participate
GOG-0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed
Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for
Optimally Debulked, Advanced Endometrial – RTOG would like to participate
GOG-0261: A Randomized Phase III trial of Carboplatin plus Paclitaxel VERSUS
Ifosfamide plus Paclitaxel in Chemotherapy Naïve Patients with Newly Diagnosed Stage
I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the
Uterus – Interested groups: NCRI, GINECO, JGOG, RTOG
NCIC CTG
NCIC CTG IND192: Ridaforolimus in Treating Patients with Recurrent Metastatic
and/or Locally Advanced Endometrial Cancer
NCIC CTG IND ###: Completing phase I of temsirolimus, taxol, and carboplatin;
have an expanded cohort in endometrial cancer that will continue;
NCIC CTG EN 8: Randomized Phase III Study of progestational hormone therapy
versus deforolimus in women with recurrent or metastatic endometrial cancer
After 4: A Phase III intergroup trial on adjuvant therapy in radically operated
endometrial cancer patients with high risk for micro-metastatic disease: 4 courses of
adjuvant CT (CT) followed by radiation therapy (RT) versus 2 more courses of CT
3